Although this study has successfully identified the genomic breakpoint of PLEKHA1-TACC2 in ESCC 1, genomic breakpoints in other tumors harboring PLEKHA1-TACC2 transcripts could not be assessed owing to technical limitations of long-range PCR. This evidence concerns the gene PLEKHA1 and esophageal squamous cell carcinoma.